Report of Foreign Issuer (6-k)
2017年10月21日 - 5:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated October 20, 2017
Commission File Number 001-35428
PRIMA BIOMED
LTD
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
Level 12, 95 Pitt Street
Sydney, 2000 New South Wales, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
EXPLANATORY NOTE
Furnished as Exhibit 99.1 hereto is a copy of our news release US and Australian Warrants Cleansing Prospectuses, dated October 20,
2017, and accompanying attachments. The U.S. prospectus referenced therein has been omitted and was separately filed on October 19, 2017 with the Securities and Exchange Commission as part of our registration statement on Form
F-3
(file no.
333-221021)
(the Registration Statement), and such Registration Statement, including the accompanying U.S. prospectus, is incorporated by
reference herein.
The Registration Statement has been filed with the Securities and Exchange Commission but has not yet become effective. The securities
offered thereby may not be sold nor may offers to buy be accepted prior to the time the registration becomes effective.
EXHIBIT INDEX
|
|
|
Exhibit
|
|
Description of Exhibit
|
|
|
99.1
|
|
US and Australian Warrants Cleansing Prospectuses
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
Dated: October 20, 2017
|
|
|
PRIMA BIOMED LTD
|
|
|
By:
|
|
/s/ Marc Voigt
|
Name: Marc Voigt
|
Title: Chief Executive Officer
|
Immutep Limited (NASDAQ:PBMD)
過去 株価チャート
から 8 2024 まで 9 2024
Immutep Limited (NASDAQ:PBMD)
過去 株価チャート
から 9 2023 まで 9 2024